Comparison of four basic models of indirect pharmacodynamic responses
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Four basic models for characterizing indirect pharmacodynamic responses after drug administration have been developed and compared. The models are based on drug effects (inhibition or stimulation) on the factors controlling either the input or the dissipation of drug response. Pharmacokinetic parameters of methylprednisolone were used to generate plasma concentration and response-time profiles using computer simulations. It was found that the responses produced showed a slow onset and a slow return to baseline. The time of maximal response was dependent on the model and dose. In each case, hysteresis plots showed that drug concentrations preceded the response. When the responses were fitted with pharmacodynamic models based on distribution to a hypothetical effect compartment, the resulting parameters were dose-dependent and inferred biological implausibility. Indirect response models must be treated as distinct from conventional pharmacodynamic models which assume direct action of drugs. The assumptions, equations, and data patterns for the four basic indirect response models provide a starting point for evaluation of pharmacologie effects where the site of action precedes or follows the measured response variable.
- N. H. G. Holford and L. B. Sheiner. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models.cin Pharmacokin. 6:429–453 (1981).
- L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine.Clin Pharmacol Ther. 25:358–371 (1979).
- D. Verotta, S. L. Beal, and L. B. Sheiner. Semiparametric approach to pharmacokinetic-pharmacodynamic data.Am. J. Physiol. 256:R1005-R1010 (1989).
- N. H. G. Holford and L. B. Sheiner. Pharmacokinetic and pharmacodynamic modeling in vivo.CRC Crit. Rev. Bioeng. 5:273–322 (1981).
- R. L. Lalonde. In W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.),Applied Pharmacokinetics, 3rd ed., Applied Therapeutics, Vancouver, 1992, pp. 4–33.
- R. Nagashima, R. A. O'Reilly, and G. Levy. Kinetics of pharmacologie effects in man: The anticoagulant action of warfarin.Clin. Pharmacol. Ther. 10:22–35 (1969).
- P. H. Abbrecht, T. J. O'Leary, and D. M. Behrendt. Evaluation of a computer-assisted method for individualized anticoagulation: Retrospective and prospective studies with a pharmacodynamic model.Clin. Pharmacol. Ther. 32:129–136 (1982).
- A.-N. Kong, E. A. Ludwig, R. L. Slaughter, P. M. Distefano, J. Demasi, E. Middleton Jr., and W. J. Jusko. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects.Clin. Pharmacol. Ther. 46:616–628 (1989).
- J. A. Wald, D. E. Salazar, H. Cheng, and W. J. Jusko. Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics.J. Pharmacokm. Biopharm. 19:521–536 (1991).
- L. E. Fisher, E. A. Ludig, and W. J. Jusko. Pharmacoimmunodynamics of methylprednisolone: Trafficking of helper T lymphocytes.J. Pharmacokin. Biopharm. 20:319–331 (1992).
- Z.-X. Xu and W. J. Jusko. Pharmacodynamic modeling of prednisolone effects on natural killer cell trafficking, (submitted for publication)
- P. Francheteau, J.-L. Steimer, C. Dubray, and D. Lavene. Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: Application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922.J. Pharmacokin. Biopham. 19:287–309 (1991).
- J. A. Wald and W. J. Jusko. Corticosteroid pharmacodynamic modeling: Osteocalcin suppression by prednisolone.Pharm. Res. 9:1096–1098 (1992).
- F. D. Boudinot, R. D'Ambrosio, and W. J. Jusko. Receptor-mediated pharmacodynamics of prednisolone in the rat.J. Pharmacokin. Biopharm. 14:469–493 (1986).
- B. Oosterhuis, R. J. M. Ten Berge, H. P. Sauerwein E. Endert, P. T. A. Schellekens, and C. J. Van Boxtel. Pharmacokinetic-pharmacodynamic modeling of prednisolone-induced lymphocytopenia in man.J. Pharmacol. Exp. Ther. 229:539–546 (1984).
- H. Derendorf, H. Mollmann, M. Krieg, S. Tunn, C. Mollmann, J. Barth, and H.-J. Bothig. Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers.Pharm. Res. 8:263–268 (1991).
- S. K. Gupta, J. C. Ritchie, E. G. Ellinwood, K. Wiedemann, and F. Holsboer. Modeling the pharmacokinetics and pharmacodynamics of dexamethasone in depressed patients.Eur. J. Clin. Pharmacol. 43:51–55 (1992).
- J. H. Lin. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists—relationship between intrinsic potency and effective plasma concentrations.Clin. Pharmacokin. 20:218–236 (1991).
- O. P. Ganda, C. B. Kahn, J. S. Soeldner, and R. E. Gleason. Dynamics of tolbutamide, glucose, and insulin: Interrelationships following varying doses of intravenous tolbutamide in normal subjects.Diabetes.24:354–361 (1975).
- G. G. Belz, W. Kirch, and C. H. Kleinbloesem. Angiotensin-converting enzyme inhibitors: relationship between pharmacodynamics and pharmacokinetics.Clin. Pharmacokin. 15:295–318 (1988).
- M. Averbuch, M. Weintraub, J. C. Liao, R. K. Brazzell, and R. E. Dobbs. Red blood cell sorbitol lowering effects and tolerance of single doses of AL 1576 (HOE 843) in diabetic patients.J. Clin. Pharmacol. 28:757–761 (1988).
- G. Movin-Osswald and M. Hammarlund-Udenaes. Remoxipride: pharmacokinetics and effect on plasma prolactin.Br. J. Clin. Pharmacol. 32:355–360 (1991).
- G. Alvan, L. Helleday, A. Lindholm, E. Sanz, and T. Villen. Diuretic effect and diuretic efficiency after intravenous dosage of frusemide.Br. J. Clin. Pharmacol. 29:215–219 (1990).
- Comparison of four basic models of indirect pharmacodynamic responses
Journal of Pharmacokinetics and Biopharmaceutics
Volume 21, Issue 4 , pp 457-478
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- indirect response
- effect compartment model
- sigmoidE max model
- Industry Sectors
- Author Affiliations
- 1. Department of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo, 14260, Buffalo, New York
- 2. Philadelphia College of Pharmacy and Science, 600 South Forty-Third Street, 19104-4495, Philadelphia, Pennsylvania